QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL EBITDA Margin
EBITDA as a percentage of revenue.
QuidelOrtho CorporationNASDAQ: QDEL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 13.1%
EBITDA Margin was 13.1% in Q1 FY2026, down 7.2 pp from a year earlier. On a trailing-twelve-month basis it was -20.7%, down 31.1 pp year over year. Over 3 fiscal years it narrowed by 51.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 25.3% for the fiscal year ending Dec 2026, up from -17.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 13.1%+7.2 pp QoQ
- Last fiscal yearDec 2025
- -17.9%+35.7 pp YoY
- LTMMar 2026
- -20.7%-31.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.2 pp | +20.1 pp | +27.3 pp |
| 1 year | +35.7 pp | +43.1 pp | +7.5 pp |
| 3 years | -51.4 pp | +43.6 pp | +95.0 pp |
| 5 years | +37.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -17.9%
- Year-over-year change
- +35.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | -17.9% | +35.7pp |
| FY2024 | 2024-12-29 | -53.5% | -73.8pp |
| FY2023 | 2023-12-31 | 20.2% | -13.2pp |
| FY2022 | 2023-01-01 | 33.5% | -22.6pp |
| FY2021 | 2021-12-31 | 56.1% | — |
EBITDA Margin vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's LTM Mar 2026 EBITDA Margin of -20.7% is the 8th highest of the 9 companies compared; the peer median is 19.7%.
- Its year-over-year change of -31.1 pp is the 8th highest of 9, against a peer median of -2.6 pp.
- Over three fiscal years its change of -51.4 pp compares with a peer median of +0.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | 66.7% | +35.3 pp | +24.1 pp |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Sep 2026 | 23.7% | -2.2 pp | -0.9 pp | |
| LTM Jun 2026 | 19.9% | -6.2 pp | +208.5 pp | |
| LTM Sep 2026 | 19.4% | -0.3 pp | +1.5 pp | |
| LTM Mar 2026 | -6.0% | -27.8 pp | +20.2 pp | |
| LTM Dec 2025 | -19.5% | +7.9 pp | -22.1 pp | |
| LTM Mar 2026 | -20.7% | -31.1 pp | -51.4 pp | |
| LTM Mar 2026 | -56.4% | -42.7 pp | -49.1 pp | |
| Peer median (excluding QDEL) | 19.7% | -2.6 pp | +0.3 pp | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.7B | 3.27B | 3B | 2.78B | 2.73B |
| Cost of Revenue | 420.3M | 1.33B | 1.5B | 1.5B | 1.46B |
| Gross Profit | 1.28B | 1.94B | 1.5B | 1.29B | 1.27B |
| Gross Margin | 75.3% | 59.3% | 49.9% | 46.2% | 46.7% |
| Research & Development | 95.7M | 187.9M | 246.8M | 218.7M | 186.2M |
| Selling, General & Admin | 239.6M | 621M | 763.2M | 766.8M | 746.3M |
| Operating Expenses | 372.3M | 1.09B | 1.36B | 3.25B | 2.19B |
| Depreciation & Amortization | 52.7M | 283.6M | 457.2M | 453.4M | 442M |
| EBITDA | 953.3M | 1.09B | 607M | (1.49B) | (488.1M) |
| EBITDA Margin | 56.1% | 33.5% | 20.2% | -53.5% | -17.9% |
| Operating Income | 906M | 843.7M | 139.1M | (1.96B) | (919.2M) |
| Operating Margin | 53.3% | 25.8% | 4.6% | -70.5% | -33.7% |
| Interest Income | 300K | 1.3M | 2.2M | 0 | 0 |
| Interest Expense | 700K | 74.5M | 178.9M | 188.3M | 177.6M |
| Other Income / Expenses | (5.7M) | (107.8M) | (168.2M) | (170.6M) | (188.5M) |
| Income Before Tax | 900.3M | 735.9M | (29.1M) | (2.13B) | (1.11B) |
| Pre-Tax Margin | 53.0% | 22.5% | -1.0% | -76.6% | -40.6% |
| Income Tax Expense | 196.1M | 187.2M | (19M) | (79.5M) | 24.1M |
| Net Income | 704.2M | 548.7M | (10.1M) | (2.05B) | (1.13B) |
| Net Margin | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% |
| EPS (Basic) | 16.74 | 9.66 | (0.15) | (30.54) | (16.69) |
| EPS (Diluted) | 16.43 | 9.56 | (0.15) | (30.54) | (16.69) |
| Weighted Avg Shares | 42.08M | 56.8M | 66.8M | 67.2M | 67.8M |
| Weighted Avg Shares (Diluted) | 42.87M | 57.4M | 66.8M | 67.2M | 67.8M |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.